secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001104659-24-059667
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics reports Q1 results; cosibelimab BLA resubmission targeted for mid-2024
--------------------------------------------------------------------------------

- Cash and equivalents $11.2M at March 31, 2024, up from $4.9M at Dec 31, 2023 after $14.0M offering.
- Net loss $10.9M ($0.33/sh) vs $10.5M ($0.89/sh) in Q1 2023; R&D expenses fell to $8.5M from $15.8M.
- Third-party CMO submitted response to FDA inspection deficiencies from Dec 2023 CRL; company plans FDA meeting for mid-year BLA resubmission.
- Board appointed Dr. Amit Sharma, VP at Alexion/AstraZeneca, as non-executive director in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/0001104659-24-059667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/tm2413887d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer